BIMZELX® Approved by the US FDA for the Treatment of Adults with Moderate to Severe Plaque Psoriasis

Bimekizumab is the first and only approved psoriasis treatment designed to selectively inhibit two key cytokines driving inflammatory processes – interleukin 17A and interleukin 17F.